SAMSCA® (tolvaptan) preserves electrolytes1
- No significant change in urinary excretion of [Na+] and [K+] or plasma [K+]
- During initiation and titration, frequently monitor for changes in serum electrolytes and volume
Exposure and response - renal function
- Exposure and response to tolvaptan in healthy subjects with creatinine clearance ranging between 79 and 10 mL/min and patients with normal renal function are not different
- SAMSCA is not recommended in patients with creatinine clearance <10 mL/min because drug effects on serum sodium levels are likely lost at very low levels of renal function
![Otsuka](/sites/g/files/qhldwo5351/files/2017-11/callout-header-moa_0.jpg)
The SAMSCA MOA video illustrates the relationship between vasopressin and hyponatremia, as well as the potential benefits of vasopressin V2-receptor antagonism.